Alan Mateo Sells 3,391 Shares of Veeva Systems Inc. (NYSE:VEEV) Stock

Veeva Systems Inc. (NYSE:VEEV) EVP Alan Mateo sold 3,391 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $200.86, for a total transaction of $681,116.26. Following the transaction, the executive vice president now owns 21,983 shares in the company, valued at approximately $4,415,505.38. The sale was disclosed in a filing with the SEC, which is available at this link.

Veeva Systems Stock Performance

VEEV stock opened at $200.95 on Wednesday. The firm has a market cap of $32.42 billion, a PE ratio of 62.41, a P/E/G ratio of 2.00 and a beta of 0.74. The firm’s fifty day moving average is $220.53 and its 200 day moving average is $202.75. Veeva Systems Inc. has a one year low of $160.21 and a one year high of $236.90.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings results on Thursday, February 29th. The technology company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. The company had revenue of $630.62 million for the quarter, compared to analyst estimates of $620.75 million. Veeva Systems had a net margin of 22.24% and a return on equity of 11.26%. Research analysts predict that Veeva Systems Inc. will post 4.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

VEEV has been the topic of a number of recent analyst reports. Robert W. Baird upped their price target on shares of Veeva Systems from $245.00 to $251.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. KeyCorp upped their price target on shares of Veeva Systems from $232.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, March 5th. Barclays upped their price target on shares of Veeva Systems from $240.00 to $245.00 and gave the company an “overweight” rating in a research note on Friday, March 1st. Oppenheimer restated an “outperform” rating and set a $225.00 price target on shares of Veeva Systems in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $250.00 price target on shares of Veeva Systems in a research note on Wednesday, March 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Veeva Systems currently has a consensus rating of “Moderate Buy” and an average target price of $234.90.

Institutional Trading of Veeva Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. OFI Invest Asset Management purchased a new position in Veeva Systems during the third quarter valued at $25,000. Operose Advisors LLC purchased a new position in Veeva Systems during the third quarter valued at $29,000. DSM Capital Partners LLC purchased a new position in Veeva Systems during the fourth quarter valued at $29,000. Vermillion & White Wealth Management Group LLC purchased a new position in Veeva Systems during the fourth quarter valued at $32,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Veeva Systems by 81.9% during the third quarter. Parkside Financial Bank & Trust now owns 171 shares of the technology company’s stock valued at $35,000 after purchasing an additional 77 shares in the last quarter. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.